Chief Executive Officer, Alexion (AstraZeneca Rare Disease)
Appears in 1 story
Leading Alexion as Ultomiris wins its fifth US indication
The US Food and Drug Administration (FDA) cleared AstraZeneca's Ultomiris on Thursday as the first complement inhibitor approved to cut proteinuria — excess protein in the urine — in adults with primary immunoglobulin A nephropathy (IgAN). The approval is accelerated, so AstraZeneca still must show the drug preserves kidney function or risk losing the indication.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
